Godrej Agrovet Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q4 FY26 earnings call analysis: revenue, margin, capex, fundraise and order book outlook from management commentary.

Published 17 Aug 2026 | Food Products | Market Cap: ₹11.2K Cr

Astec LifeSciences**: Targeting around 15%-20% top-line growth, with CDMO segment expected to grow slightly higher than the enterprise segment; margins to remain intact. Godrej Agrovet aims for early double-digit revenue growth at the consolidated level for FY27.

From Godrej Agrovet Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Price

575

Market Cap

₹11.2K Cr

P/E Ratio

23.8

How does Godrej Agrovet Ltd rank in Food Products?

Compare Godrej Agrovet Ltd against every Food Products company this quarter on revenue, margins and earnings-call signals.

View Food Products leaderboard →

Godrej Agrovet Ltd — Quarterly revenue & net profit

Revenue Net Profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹2.3K Cr, net profit ₹102 Cr.

Full financials →

📊 Revenue & Sales Performance

  • **Astec LifeSciences**: Targeting around 15%-20% top-line growth, with CDMO segment expected to grow slightly higher than the enterprise segment; margins to remain intact. CDMO revenue share aimed at 52%-53%+.
  • **Animal Nutrition**: Strong volume growth continuing, particularly in cattle feed and newly launched products; focusing on volume-driven revenue growth with double-digit growth expected.
  • **Oil Palm**: Early double-digit volume growth expected, with record area expansion planned; improving oil extraction ratio supports margins.
  • **Crop Care**: Expected strong recovery from Q2 FY27 onwards, aiming for very high double-digit revenue growth post inventory normalization.
  • **Godrej Foods**: Continued double-digit growth in branded products; phased exit from live bird trading with growth in value-added segments like frozen chicken and momos.
  • **Overall FY27 Outlook**: Early double-digit consolidated revenue growth; mid-teens PBT growth targeted, driven mostly by volume expansion.

See what Godrej Agrovet Ltd said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

  • Godrej Agrovet plans capex of around INR 350-400 crores per year going forward.
  • Approximately 75%-80% of capex will be growth-oriented.
  • Around 50% of total capex deployment is targeted toward the Oil Palm business.
  • Specific investments include rolling out a specialty fat refinery starting May FY '27, expected to ramp up in the second half of the year.
  • Investment focus on value-added products in Oil Palm to move the portfolio towards 50%-55% value-added products by FY31.
  • Ongoing strategic restructuring and portfolio reviews to unlock shareholder value over a 4-5 year horizon.
  • Emphasis on capacity expansion in animal nutrition, crop care diversification, and new product development.
  • Focus on backward integration in the CDMO business to mitigate supply risks and improve cost competitiveness.

See what Godrej Agrovet Ltd said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

The transcript from the provided pages does not explicitly mention the current or expected order book or pending orders for Godrej Agrovet Limited. However, relevant insights include: - Astec LifeSciences is witnessing a positive trend with a strong comeback led by CDMO. - The pipeline funnels for Astec CDMO business are looking pretty good, with some good early leads emerging. - The company expects growth around 15-20% in Astec’s CDMO business. - Strategic focus is on increasing value-added portfolio in Crop Care and Oil Palm segments. - Expansion plans include record-breaking area expansion for Oil Palm next year. - Emphasis on volume-driven revenue growth across businesses. - No specific figures on order book or pending orders are provided in the discussed pages. If you need details on order book or pending orders, it may require further document sections or a formal data request.

Key Metrics

How does Godrej Agrovet Ltd rank vs peers in Food Products?

Pro feature
1Godrej Agrovet Ltd

See full Food Products sector rankings

Others in Food Products this season

  • HOACFOODS (Q4 FY26)

    Online sales are growing fast, constituting 10% of sales; plans to expand into quick commerce platforms with smaller packaging for better margins. Key concall…

  • DSM Fresh Foods Ltd (Q4 FY26)

    Export markets (US, Canada, Europe) will support ready-to-eat growth, currently at ~INR 40 crore run rate. Key concall takeaways from DSM Fresh's Q4 FY26…

  • Parag Milk Foods Ltd (Q4 FY26)

    The company is confident in sustaining gross margins around 27-28%, supported by pricing power and product mix improvements. Key concall takeaways from Parag…

  • HERITGFOOD (Q4 FY26)

    Current CAPEX of approximately INR 380 crores primarily spent on plant production capacity expansion. Key concall takeaways from Heritage Foods Ltd's Q4 FY26…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Godrej Agrovet Ltd Q4 FY26 results?

Astec LifeSciences**: Targeting around 15%-20% top-line growth, with CDMO segment expected to grow slightly higher than the enterprise segment; margins to remain intact. Godrej Agrovet aims for early double-digit revenue growth at the consolidated level for FY27.

What is Godrej Agrovet Ltd share price analysis?

Godrej Agrovet Ltd currently shows a neutral. The stock trades at a P/E of 23.8 with a market cap of ₹11,166 Cr. Investors should review the full earnings analysis for detailed insights.

Is Godrej Agrovet Ltd planning capital expenditure?

Godrej Agrovet plans capex of around INR 350-400 crores per year going forward.

Keep Godrej Agrovet Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.